KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Receivables (2016 - 2025)

Historic Receivables for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $441.3 million.

  • Halozyme Therapeutics' Receivables rose 3422.55% to $441.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $441.3 million, marking a year-over-year increase of 3422.55%. This contributed to the annual value of $441.3 million for FY2025, which is 3422.55% up from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Receivables is $441.3 million, which was up 3422.55% from $346.0 million recorded in Q3 2025.
  • Over the past 5 years, Halozyme Therapeutics' Receivables peaked at $441.3 million during Q4 2025, and registered a low of $92.1 million during Q4 2021.
  • In the last 5 years, Halozyme Therapeutics' Receivables had a median value of $226.5 million in 2022 and averaged $234.3 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Receivables soared by 31314.67% in 2021 and then plummeted by 2749.11% in 2023.
  • Halozyme Therapeutics' Receivables (Quarter) stood at $92.1 million in 2021, then surged by 150.85% to $231.1 million in 2022, then grew by 1.79% to $235.2 million in 2023, then surged by 39.77% to $328.8 million in 2024, then skyrocketed by 34.23% to $441.3 million in 2025.
  • Its Receivables stands at $441.3 million for Q4 2025, versus $346.0 million for Q3 2025 and $316.3 million for Q2 2025.